West Pharmaceutical Services Inc. ($WST) Stock Forecast: Up 5.0% Today

What is West Pharmaceutical Services Inc.?

West Pharmaceutical Services (WST) is a medical instruments supplier specializing in packaging and delivery systems for injectable drugs and healthcare products, prioritizing innovation and quality to serve the healthcare industry.

Why is West Pharmaceutical Services Inc. going up?

WST stock is up 5.0% on Feb 4, 2026 18:06

• West Pharmaceutical Services (WST) witnessed a strong bullish movement in the market today, with the following factors contributing to this positive trend:
• Analysts maintaining a "Buy" consensus rating for WST, setting an average target price of $335.78, reflecting confidence in the company's future performance.
• Truist Financial Corp significantly increased its stake in WST by 73.7% in the third quarter, indicating strong institutional investor confidence in the company's growth prospects.
• Despite a slight decrease in the average one-year price target for WST, the new target still represents a notable 23.61% increase from the latest closing price, showcasing optimism about the company's potential.
• The recent launch of DuPont's new Liveo C6-8XX Liquid Silicone Rubber series for healthcare applications might have indirectly influenced investor sentiment towards WST, highlighting the continuous innovation and advancements in the healthcare sector where WST operates.

WST Price Chart

WST Technical Analysis

WST News

Will The Cooper Companies (COO) Beat Estimates Again in Its Next Earnings Report?

The Cooper Companies (COO) is expected to continue its earnings-beat streak in its upcoming report, as indicated by a positive Zacks Earnings ESP of +0.24% and a Zacks Rank #2 (Buy). The company has consistently topped earnings estimates in its last two reports, with an average surprise of 3.20%. These factors suggest a high probability of another positive surprise for the surgical and contact lens products maker.

https://finviz.com/news/297933/will-the-cooper-companies-coo-beat-estimates-again-in-its-next-earnings-report

Reasons to Add Cooper Companies Stock to Your Portfolio Now

The Cooper Companies (COO) is positioned for growth due to strong performance in its CooperVision segment, particularly with its MyDay premium lens portfolio, and advancements in CooperSurgical's women's health and fertility offerings. While the company anticipates meaningful margin and free cash flow expansion, it faces challenges from gross margin pressures related to product mix and tariffs, as well as weakness in the Asia-Pacific market and uncertainty in the fertility sector. Despite these headwinds, the company's aggressive shareholder returns, disciplined capital allocation strategy, and positive long-term growth estimates make it an attractive investment.

https://sg.finance.yahoo.com/news/reasons-add-cooper-companies-stock-181700882.html

West Pharmaceutical Services (BIT:1WST) Price Target Decreased by 11.92% to 278.11

The average one-year price target for West Pharmaceutical Services (BIT:1WST) has been decreased by 11.92% to €278.11 per share from €315.77. This new target represents a 23.61% increase from the latest closing price of €225.00. Institutional ownership shows varied activity, with PCSCX increasing its stake significantly while Brown Advisory decreased its portfolio allocation.

https://www.nasdaq.com/articles/west-pharmaceutical-services-bit-1wst-price-target-decreased-1192-27811

DuPont Launches Liveo C6-8XX Liquid Silicone Rubber Series for Healthcare Applications

DuPont has launched its new Liveo C6-8XX Liquid Silicone Rubber (LSR) series, a medical-grade, two-part silicone elastomer designed for demanding healthcare applications. This series offers improved rheology and lower viscosity, enabling more efficient molding cycles for medical device fabrication, including non-implant and short-term implant components. The products meet USP Class VI and select EP regulatory requirements, emphasizing flexibility, reliability, and biocompatibility for medical device manufacturers.

https://finviz.com/news/297301/dupont-launches-liveo-c6-8xx-liquid-silicone-rubber-series-for-healthcare-applications

Truist Financial Corp Has $7.64 Million Position in West Pharmaceutical Services, Inc. $WST

Truist Financial Corp increased its stake in West Pharmaceutical Services (NYSE:WST) by 73.7% in the third quarter, bringing its total holdings to 29,107 shares valued at $7.64 million. Other institutional investors like Vanguard Group, State Street Corp, and Invesco Ltd. also adjusted their positions in the medical instruments supplier. Analysts maintain a "Buy" consensus rating for WST, with an average target price of $335.78, and the company recently declared a quarterly dividend of $0.22 per share.

https://www.marketbeat.com/instant-alerts/filing-truist-financial-corp-has-764-million-position-in-west-pharmaceutical-services-inc-wst-2026-02-03/

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 7.7% Today

S&P 500 Index ($SPX) Index Forecast: Down 1.3% Today

XRP ($XRP) Crypto Forecast: Down 14.3% Today

Bitcoin ($BTC) Crypto Forecast: Down 8.9% Today

Natural Gas ($GAS) Commodity Forecast: Up 5.6% Today

ZCash ($ZEC) Crypto Forecast: Down 12.9% Today

Monero ($XMR) Crypto Forecast: Down 7.9% Today

Tezos ($XTZ) Crypto Forecast: Down 5.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.1% Today

Cardano ($ADA) Crypto Forecast: Down 6.3% Today

West Pharmaceutical Services Inc. Price History

04.01.2026 - WST Stock was up 5.0%

• West Pharmaceutical Services (WST) witnessed a strong bullish movement in the market today, with the following factors contributing to this positive trend:
• Analysts maintaining a "Buy" consensus rating for WST, setting an average target price of $335.78, reflecting confidence in the company's future performance.
• Truist Financial Corp significantly increased its stake in WST by 73.7% in the third quarter, indicating strong institutional investor confidence in the company's growth prospects.
• Despite a slight decrease in the average one-year price target for WST, the new target still represents a notable 23.61% increase from the latest closing price, showcasing optimism about the company's potential.
• The recent launch of DuPont's new Liveo C6-8XX Liquid Silicone Rubber series for healthcare applications might have indirectly influenced investor sentiment towards WST, highlighting the continuous innovation and advancements in the healthcare sector where WST operates.

24.06.2025 - WST Stock was up 23.7%

• WST stock surged as the company reported a strong Q2 earnings beat, driven by an increase in earnings per share due to tariff and foreign exchange benefits.
• Revenue growth in the Proprietary Products segment played a key role in the positive market movement, signaling robust demand for high-value products like GLP-1 and SmartDose.
• Investor sentiment remains upbeat about West Pharmaceutical's ability to sustain growth in Q2, buoyed by ongoing strength in critical segments.
• Bullish investor confidence today was likely strengthened by the favorable earnings outlook and segmental performance expectations for West Pharmaceutical Services, Inc.

06.05.2025 - WST Stock was up 5.5%

• The bullish movement in WST stock could be attributed to investors' optimism regarding the pending class action lawsuit.
• The reminder of the lawsuit deadline might have sparked confidence in the market, indicating that the company is taking necessary legal actions to address any potential issues.
• This proactive approach from West Pharmaceutical Services, Inc. could have reassured investors and led to increased buying interest, driving the stock price higher.
• Overall, the market's positive reaction to the news of the pending class action lawsuit reflects investor confidence in the company's ability to handle legal challenges effectively.

06.00.2026 - WST Stock was up 5.7%

• Despite executive insider selling and recent performance challenges, West Pharmaceutical Services Inc. exceeded expectations with its Q3 earnings and revenue. This likely contributed to the positive movement in the company's stock.
• The growing investments from North Growth Management Ltd. and Ethic Inc. in WST suggest increasing confidence in the company's future, especially with the optimistic FY2025 guidance provided.
• Thermo Fisher Scientific Inc. ($TMO) recently announced a quarterly dividend and a stock buyback program, potentially boosting market sentiment towards healthcare companies, including WST.
• In summary, West Pharmaceutical Services Inc.'s bullish stock movement today could be attributed to its strong financial performance, increased stake acquisitions, and positive developments in the healthcare sector.

21.10.2025 - WST Stock was up 5.1%

• The decrease in short interest indicates a positive sentiment among investors towards WST.
• The reduction in shares sold short could suggest that investors are becoming more confident in the company's future prospects.
• This decrease in short interest may have contributed to increased buying pressure on WST, leading to its bullish movement today.

16.00.2026 - WST Stock was down 4.2%

• Institutional investor Conning Inc. decreased its stake in AbbVie Inc., suggesting a potential shift in focus away from traditional pharmaceutical companies like AbbVie. This shift could impact related stocks such as WST.
• Analysts indicate that WST may be overvalued at its current price. Concerns about revenue headwinds and project conversion risks likely contributed to the stock's bearish movement.
• Despite positive growth prospects in the GLP-1 market and regulatory upgrades, challenges including revenue headwinds and profitability risks may have overshadowed the positive outlook, leading to the bearish market movement.
• The combination of reduced institutional investment in AbbVie, concerns about WST's overvaluation and revenue challenges, and potential risks in project conversions likely influenced the bearish movement in WST's stock today.

23.06.2025 - WST Stock was up 5.3%

• WST's strong bullish movement today could be attributed to the market's anticipation of steady growth in Q2 earnings, driven by the high demand for GLP-1 and SmartDose products.
• Investors may be optimistic about WST's segmental edge holding up, leading to increased confidence in the company's performance.
• The focus on innovation and meeting the demand for healthcare products could be positioning WST favorably in the market, attracting investor interest and driving the stock's upward movement.

23.00.2026 - WST Stock was down 6.9%

• Despite positive developments like the sale of SmartDose rights to AbbVie and a "strong-buy" rating from Zacks Research, WST saw a decline in its market value today.
• The market's negative reaction may be attributed to concerns about the impact of selling a product that contributed significantly to WST's revenue in 2025, leading to uncertainties regarding future earnings.
• While the industry outlook is favorable and growth prospects are promising, investors may be wary of WST's strategic shift and the challenges highlighted in recent reports.
• The extended collaboration between BD and Ypsomed to target the expanding biologics market could intensify competition in the drug delivery systems sector, creating additional pressure on WST's market standing.

10.06.2025 - WST Stock was up 4.0%

• The rise in WST's stock price could be due to investors' growing confidence in the company's ability to manage the class action lawsuit situation.
• Initially, the announcement of investors having the chance to lead a class action lawsuit caused uncertainty and a decrease in the stock price.
• However, as more investors engage legal support to discuss their rights before the deadline, it suggests a potential positive resolution for the company, leading to the stock's upward movement.
• This scenario emphasizes the significance of monitoring legal developments and investor sentiment alongside the company's operational performance when evaluating stock fluctuations.

23.09.2025 - WST Stock was up 14.5%

• The bullish movement in WST could be attributed to the anticipation of strong Q3 earnings driven by robust demand for GLP-1 and biologics products.
• Investors seem optimistic about WST's ability to navigate challenges such as labor constraints, tariffs, and plant shutdowns, which might have positively impacted the stock price.
• The market may be pricing in the potential for WST to outperform expectations despite margin pressures, showcasing confidence in the company's resilience and growth prospects.

23.09.2025 - WST Stock was up 10.7%

• WST stock experienced a bullish movement today due to the company's strong Q3 earnings beat and raised EPS outlook, driven by robust demand and favorable foreign exchange rates.
• The market responded positively to the company's solid growth in Proprietary Products, reflecting investors' confidence in West Pharmaceutical's ability to capitalize on market opportunities.
• Despite potential challenges such as labor constraints, tariffs, and plant shutdowns, the momentum in GLP-1 and biologics demand seems to have outweighed any margin pressure concerns, further boosting investor sentiment towards WST stock.

06.10.2025 - WST Stock was down 4.0%

• Analysts are bullish on WST, predicting a potential surge of 25.41% in the stock price.
• Despite positive analyst sentiment, the market may have reacted to other factors causing a bearish movement in WST.
• It is possible that external market conditions or unforeseen events impacted WST negatively, leading to the bearish trend observed today.